Sensus Healthcare’s analyst narrative has shifted, with one price target now set at US$7.50 and another adjusted to US$6 from US$8. Supportive research ties the US$7.50 view to confidence in the ...
Cadre (NYSE:CDRE) executives used the company’s fourth-quarter 2025 earnings call to highlight expanding backlog, recent contract wins across public safety and defense end markets, and an increased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results